CD19 antibody
Principal name
CD19 antibody
Alternative names for CD19 antibody
Leu-12, B-cell marker, Differentiation antigen CD19, B-lymphocyte surface antigen B4
Ncbi ID
NP_001171569.1, NP_033974.2, 9606, NP_001171569, NP_033974, NP_001761, NM_001770, NM_001178098
Available reactivities
Available hosts
Available applications
Frozen Sections (C), Functional assay (FN), Flow Cytometry (F), Immunoprecipitation (IP), Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Immunocytochemistry/Immunofluorescence (ICC/IF), Paraffin Sections (P), Luminex (LMNX)
Background of CD19 antibody
CD19 is present in both normal and malignant B cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue CD19 is observed in germinal centers (on both B cells and follicular dendritic cells), in mantle zone cells and in scattered cells in the interfollicular areas, with an overall immunoreactivity pattern similar to that of CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in pre-B cells. CD19 has also been detected by flow cytometry in plasma cells isolated from human tissues. Recently, Masir et al. have described the expression of CD19 in normal lymphoid tissue and its loss in B-cell neoplasms. CD19 positivity is seen in the lymphoid follicle in germinal centers, the mantle zone, as well as in interfollicular T-cell areas including large cells with ‘dendritic’ morphology.
CD19 positivity is seen in the vast majority of B-cell neoplasms (B-lymphoblastic lymphoma, small lymphocytic lymphoma/CLL, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell-rich B-cell lymphoma, lymphoblastic lymphoma, hairy cell leukaemia) and commonly at a lower intensity than normal B-cell elements. Plasma cell neoplasms are consistently negative as are T-cell neoplasms. In the Masir study, CD19 was undetectable in 14% of diffuse large B-cell lymphomas, 30% of T-cell-rich B-cell lymphomas and 75% of post-transplant B-lymphoproliferative disease. CD19 expression is not seen in Reed-Sternberg cells of classic Hodgkin’s disease.
General readings
1. Functional Properties of CD19+ B Lymphocytes Positively Selected from Buffy Coats by Immunomagnetic Separation. Funderud S., Erikstien B., Asheim H.C., Nustad K., Stokke T., Blomhoff H.K., Holte H, Smeland E.B., Eur. J. Immunol. 1990 Ja;20(1):201-6.
2. Thymic B Cells from Myasthenia Gravis Patients are Activated B Cells. Phenotypic and Functional Analysis. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., Richard Y., J. Immunol. 1990 Oct., 145(7):2115-22.
3. Prognostic Significance of CD34 Expression in Childhood B Precursor Acute Lymphocytic Leukemia: A Pediatric Onocology Group Study. Borowitz MJ, Shuster JJ, Civin CI, Carrol AJ, Look AT, Behm FG, Land VJ, Pullen DJ, Crist WM, J. Clin. Onol. 1990 Au;8(8):1389-98.
4. Biphenotypic Acute Leukemia in Adults. Sulak LE, Clare CN, Morale BA, Hansen KL, Montiel MM, Am. J. Clin. Path. 1990 Ju;94(1):54-8.
5. Intersection of the Complement and Immune Systems: A Signal Transduction Complex of the B Lymphocyte Containing Complement Receptor type 2 and CD19. Matsumoto AK, Kopicky-Burd J., Carter Rh, Tuveson DA, Tedder TF, Fearon, DT, J. Exp. Med. 1991 Jan. 173(1):55-64.
6. Immunofluorescence Measurement in a Flow Cytometer using Low-Power Helium Neon Laser Excitation. Shapiro, H.M, Glazer, A.N., Christenson, L., Williams, J.M., and Strom, T. B. Cytometry 4,276, 1983.
7. Comparison of Helium Neon and Dye lasers for Excitation of Allophycocyanin. Loken, M.R., Kiej, J.F. and Kelly, K.,A. Cytometry 8, 96, 1987.
Portions of this product are manufactured under license from Carnegie Mellon University, U.S. Patent Number 5,268,486.
Surface staining of human peripheral blood cells with anti-human CD19 (LT19) APC.
Staining of mouse spleen cells with Rat anti Mouse CD19:APC
Staining of mouse spleen cells with RAT ANTI MOUSE CD19:FITC
Staining of Mouse spleen cells with Rat Anti Mouse CD19-RPE.
Staining of human peripheral blood lymphocytes with Mouse Anti Hunman CD19-RPE (SM1529R/RT).
Figure 1. Peripheral blood lymphocytes stained with CD19 Antibody Cat.-No AM05180RP-N (Clone 1G9).
Staining of human peripheral blood lymphocytes with mouse anti human CD19
Staining of human peripheral blood lymphocytes wioth mouse anti human CD19
Staining of mouse spleen cells with Rat Anti Mouse CD19-FITC
Staining of Mouse spleen cells with Rat Anti Mouse CD19-RPE.
Staining of Mouse spleen cells with Rat Anti Mouse CD19-RPE.
Detection limit for recombinant GST tagged CD19 is approximately 0.3ng/ml as a capture antibody.
Surface staining of human peripheral blood cells with CD19 monoclonal antibody, clone LT19 ( Cat # MAB0921 ) APC.
Surface staining of human peripheral blood cells with CD19 monoclonal antibody, clone LT19 ( Cat # MAB0921 ) APC.
Proximity Ligation Analysis (PLA) of protein-protein interactions between CD19 and CD82. HeLa cells were stained with anti-CD19 rabbit purified polyclonal 1:1200 and anti-CD82 mouse monoclonal antibody 1:50. Signals were detected by Duolink® 30 Detection Kit 613(red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.
CD19 MaxPab rabbit polyclonal antibody. Western Blot analysis of CD19 expression in mouse kidney.
Western Blot analysis of CD19 expression in transfected 293T cell line (H00000930-T01) by CD19 MaxPab polyclonal antibody.Lane 1: CD19 transfected lysate(61.10 KDa).Lane 2: Non-transfected lysate.
Cells from BALB/c mesenteric lymph nodes were double-stained with Cd19 monoclonal antibody, clone 6D5 ( Cat # MAB3226 )-FITC and anti-mouse CD3-R-PE, gated on small lymphocytes and analyzed on a FACScanTM flow cytometer ( BDIS, San Jose, CA ).
Surface staining of human peripheral blood cells with CD19 monoclonal antibody, clone LT19 (APC) ( Cat # MAB4369 ).
Flow Cytometry using human peripheral blood cells ( 1 µg/106 cells ).FACSCalibur ( Becton Dickinson, San Jose, CA ) flow cytometer, using Cell Quest acquisition software and PAINT-A-GATE. PRO, analysis software.
Human tonsil stained with anti-CD19 antibody
Western Blot analysis of CD19 antibody (Cat.-No AP20341PU-N) at 1/500 dilution:
Lane 1: MCF-7 cell lysate.
Lane 2: Mouse spleen tissue lysate
Lane 3: Rat spleen tissue lysate.
Lane 1: MCF-7 cell lysate.
Lane 2: Mouse spleen tissue lysate
Lane 3: Rat spleen tissue lysate.
Western blot analysis of CD19 antibody (Cat.-No.: AP20344PU-N) in extracts from COS7 cells.
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
T-1355 CD19 (B-lymphocyte surface antigen B4, Leu-12) mouse anti human, clone AE1 (purified monoclonal IgG1, lyophilized)
Human Tonsil (formalin-fixed, paraffin-embedded) stained with CD19 antibody AP22796PU-N followed by biotinylated goat anti-rabbit IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Human Spleen (formalin-fixed, paraffin-embedded) stained with CD19 antibody AP22796PU-N followed by biotinylated goat anti-rabbit IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.
Surface staining of CD19 in murine splenocytes with anti-CD19 (1D3) PE.
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
Human Tonsil stained with Rabbit anti-CD19 Antibody Cat.-No AM21063PU (Clone SP110).
Flow Cytometric analysis of Rabbit anti-CD19 Antibody Cat.-No AM21063PU (Clone SP110) in RAMOS (green) compare to negative control of rabbit IgG (blue).
Immunohistochemistry on frozen sections: Stainig of human tonsil with AM26049PU-N
A typical staining pattern with the B-C3 monoclonal antibody of lymphocytes
A typical staining pattern with the B-C3 monoclonal antibody of lymphocytes
A typical staining pattern with the B-C3 monoclonal antibody of lymphocytes
A typical staining pattern with the B-C3 monoclonal antibody of lymphocytes
A typical staining pattern with the B-D3 monoclonal antibody of lymphocytes
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
Staining with clone HD37 (CD19) monoclonal antibodies is illustrated by flow cytometry analysis of normal blood cells. Direct staining was performed using 10 µl of the PE - conjugated antibody with 100 µl blood sample.
Immunohistochemical analysis of paraffin-embedded human normal lymph node, showing cytoplasmic localization using CD19 antibody Cat.-No AM06097PU-N with DAB staining.
Western blot analysis using CD19 antibody Cat.-No AM06097PU-N against CD19 recombinant protein.
Immunofluorescence analysis of HL-60(left) and K562 (right) cells using CD19 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.
Flow cytometric analysis of Raji cells using CD19 mouse mAb (green) and negative control (purple).
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
Staining of Jurkat lysate using CD19 Antibody Cat.-No AP32823PU-N at 2 µg/ml (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Formalin-Fixed, Paraffin-Embedded Human tonsil stained with CD19 Antibody Cat.-No AM32848PU (Clone C19/366) at 1/100 dilution using peroxidase-conjugate and DAB chromogen. Note specific membrane staining.
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified.
Surface staining of human peripheral blood cells with anti-human CD19 (LT19) APC.
Surface staining of human peripheral blood leukocytes with anti-human CD19 (4G7) purified (AM26006PU-N).
Western blot analysis of extracts from COS7 cells treated with Serum using Phospho-CD19 (Tyr531) antibody AP55866PU-N.The lane on the right is treated with the antigen-specific peptide.
Western blot analysis of CD19 (pY531) expression in HeLa EGF-treated (A); Raw264.7 EGF-treated (B); H9C2 EGF-treated (C) whole cell lysates.
Surface staining of CD19 in murine splenocytes with anti-CD19 (1D3) PE.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody-Biotin labled; followed by Streptavidin PE.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody-APC labled.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody-FITC labled.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody-PE labled.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody-PE-Cy5 labled.
Flow cytometric analysis of human peripheral blood lymphocytes using Anti-CD19 Antibody; followed by anti-mouse IgG PE.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Immunohistochemical staining of paraffin-embedded Human tonsil within the normal limits using anti-CD19 mouse monoclonal antibody. (TA506234; heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)
Anti-CD19 mouse monoclonal antibody (TA506234) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Flow cytometric Analysis of K562 cells, using anti-CD19 antibody(TA506234),(Red), compared to a nonspecific negative control antibody,(Blue).
Immunohistochemical staining of paraffin-embedded Human tonsil within the normal limits using anti-CD19 mouse monoclonal antibody. (TA506236; heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)
Immunohistochemical staining of paraffin-embedded Human lymphoma tissue using anti-CD19 mouse monoclonal antibody. (TA506236; heat-induced epitope retrieval by 1 mM EDTA in 10mM Tris, pH8.5, 120C for 3min)
Anti-CD19 mouse monoclonal antibody (TA506236) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Flow cytometric Analysis of K562 cells, using anti-CD19 antibody(TA506236),(Red), compared to a nonspecific negative control antibody,(Blue).
Immunohistochemical staining of paraffin-embedded Human tonsil within the normal limits using anti-CD19 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506239)
Immunohistochemical staining of paraffin-embedded Human lymphoma tissue using anti-CD19 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506239)
Anti-CD19 mouse monoclonal antibody (TA506239) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Anti-CD19 mouse monoclonal antibody (TA506240) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Flow cytometric Analysis of K562 cells, using anti-CD19 antibody(TA506240),(Red), compared to a nonspecific negative control antibody,(Blue).
Anti-CD19 mouse monoclonal antibody (TA506241) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Anti-CD19 mouse monoclonal antibody (TA506273) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Anti-CD19 mouse monoclonal antibody (TA506279) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-CD19 monoclonal antibody (HepG2: human; HeLa: human; SVT2: mouse; A549: human; COS7: monkey; Jurkat: human; MDCK: canine; PC12: rat; MCF7: human).
Anti-CD19 mouse monoclonal antibody (TA506280) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
Immunohistochemical staining of paraffin-embedded Human tonsil within the normal limits using anti-CD19 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506285)
Immunohistochemical staining of paraffin-embedded Human lymphoma tissue using anti-CD19 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min, TA506285)
Anti-CD19 mouse monoclonal antibody (TA506285) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CD19(RC202922).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD19 (RC202922, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD19.
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2F6 Detection (TA700283) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2G7 Detection (TA700285) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2F6 Capture (TA600284) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 3G7 Detection (TA700295) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 2G7 Detection (TA700285) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2D3 Capture (TA600286) and 2F6 Detection (TA700283) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2D3 Capture (TA600286) and 2B11 Detection (TA700284) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2F6 Detection (TA700283) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2D3 Capture (TA600286) and 2F6 Detection (TA700283) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2D3 Capture (TA600286) and 2B11 Detection (TA700284) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2G7 Detection (TA700285) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 2G7 Detection (TA700285) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 3G7 Capture (TA600283) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 2F6 Capture (TA600284) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 2D3 Detection (TA700286) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Luminex Elisa with 1E9 Capture (TA600285) and 3G7 Detection (TA700295) Antibodies. Substrate used: Recombinant Human CD19 (TP302922)
CD19 Antibody (C-term) (Cat.# TA302071) western blot analysis in Ramos cell line lysates (35ug/lane).This demonstrates the CD19 antibody detected the CD19 protein (arrow).
Western blot analysis of CD19 (arrow) using rabbit polyclonal CD19 Antibody (N-term) (Cat.#TA302072). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the CD19 gene (Lane 2) (Origene Technologies).
CD19 Antibody (N-term) (Cat.# TA302072) western blot analysis in Raji cell line lysates (35ug/lane).This demonstrates the CD19 antibody detected the CD19 protein (arrow).
Western blot analysis of lysate from Ramos cell line, using CD19Antibody (N-term)(Cat. #TA302072). TA302072 was diluted at 1:500. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.
Formalin-fixed and paraffin-embedded human lymph reacted with CD19 Antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
Immunofluorescence analysis of CD19 Antibody (N-term) with paraffin-embedded human lymph tissue . 0.05 mg/ml primary antibody was followed by FITC-conjugated goat anti-rabbit lgG (whole molecule). FITC emits green fluorescence.Red counterstaining is PI.
Flow cytometric analysis of CEM cells using CD19 Antibody (N-term)(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Staining of C57Bl/6 splenocytes with 0.25 ug of Rat IgG2a Isotype Control Purified (open histogram) or 0.25 ug of Anti-Mouse CD19 Purified) (filled histogram) followed by Anti-Rat IgG Biotin and Streptavidin PE . Cells in the lymphocyte gate were used for analysis.
Western blot analysis of CD19 expression in Serum treated COS7 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of extracts from COS7 cells, treated with Serum (10%, 30mins), using CD19 (Ab-531) Antibody.The lane on the right is treated with the synthesized peptide.
Immunohistochemistry staining of Paraffin Tonsil tissue by CD19 antibody (dilution: 1:25 - 1:100; visualization of staining: Membranous)
Western blot analysis of extracts of various cell lines, using CD19 antibody.
Immunohistochemical of paraffin-embedded human smooth muscle cancer using CD19 antibody at dilution of 1:200 (400x lens).
Immunohistochemical of paraffin-embedded human thyroid cancer using CD19 antibody at dilution of 1:200 (400x lens).
Immunohistochemical of paraffin-embedded human breast cancer using CD19 antibody at dilution of 1:200 (400x lens).
Immunohistochemical of paraffin-embedded rat kidney using CD19 antibody at dilution of 1:200 (400x lens).
C57BL/6 mouse splenocytes were stained with purified CD19 (clone 6D5) (filled histogram) or rat IgG2a, kappa; isotype control (open histogram), followed by anti-rat IgG FITC.
Human Tonsil stained with anti-CD19 antibody.
Flow cytometric analysis of rabbit anti-CD19 (SP110) antibody in RAMOS (green) compare to negative control of rabbit IgG (blue).
Human Tonsil stained with anti-CD19 antibody.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AM26049PU-N | CD19 antibody |
||||||
 |
Mouse | IgG1 | AE1 | Aff - Purified | Hu | C, F |
0.1 mg /
€310.00
|
| OriGene Technologies GmbH | |||||||